Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 30, 2015 4:50 AM ET


Company Overview of Ardelyx, Inc.

Company Overview

Ardelyx, Inc. discovers, develops, and commercializes minimally-systemic small molecule therapeutics for the gastrointestinal (GI) tract to treat cardio-renal, GI, and metabolic diseases. Its lead product candidate is tenapanor, a small molecule NHE3 inhibitor, which has completed Phase 2b clinical trial for the treatment of patients with constipation-predominant irritable bowel syndrome and hyperphosphatemic patients with chronic kidney disease on dialysis, as well as Phase 2a clinical trial in patients with late-stage chronic kidney disease. The company’s discovery and lead development programs that are in research phase include RDX002 NaP2b inhibitor for hyperphosphatemia; RDX009 TGR5 ago...

34175 Ardenwood Boulevard

Suite 100

Fremont, CA 94555

United States

Founded in 2007

34 Employees





Key Executives for Ardelyx, Inc.

Chief Executive Officer, President and Director
Age: 50
Total Annual Compensation: $466.0K
Chief Financial Officer
Age: 47
Total Annual Compensation: $318.9K
Senior Vice President of Drug Development
Age: 54
Total Annual Compensation: $277.5K
Chief Scientific Officer and Executive Vice President
Age: 46
Total Annual Compensation: $132.1K
Compensation as of Fiscal Year 2014.

Ardelyx, Inc. Key Developments

Ardelyx, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Announces Initiation of Clinical Trials

Ardelyx, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company's loss from operations was $18,079,000 compared to income from operations of $81,000 a year ago. Net loss and comprehensive loss was $18,126,000 or $0.58 per basic and diluted share compared to net income and comprehensive income of $74,000 a year ago. Total revenues decreased to zero in the third quarter of 2015 from $7.6 million in the third quarter of 2014 because of the termination of the AstraZeneca agreement in June 2015. For the nine months, the company's total revenue was $24,026,000 compared to $25,284,000 a year ago. Loss from operations was $12,513,000 compared to income from operations of $2,369,000 a year ago. Net loss and comprehensive income was $12,621,000 or $0.71 per basic and diluted share compared to net income and comprehensive income of $757,000 a year ago. The company also announced that two clinical trials were initiated in October 2015: a Phase 3 clinical trial evaluating tenapanor for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and a clinical study evaluating the pharmacodynamics activity of RDX022, a potassium binder for the treatment of hyperkalemia. Additionally, the company indicated that it plans to initiate a Phase 2b study to evaluate tenapanor in CKD patients with hyperphosphatemia on dialysis in December 2015. Results from this study are currently expected in the second half of 2016.

Ardelyx, Inc. to Report Q3, 2015 Results on Nov 12, 2015

Ardelyx, Inc. announced that they will report Q3, 2015 results at 1:01 PM, GMT Standard Time on Nov 12, 2015

Ardelyx, Inc., Q3 2015 Earnings Call, Nov 12, 2015

Ardelyx, Inc., Q3 2015 Earnings Call, Nov 12, 2015

Similar Private Companies By Industry

Company Name Region
SaluMedica, LLC United States
Aubrey Inc. United States
2C Tech Corporation, Inc. United States
Accelerated Pharma, Inc. United States
AorTx, Inc. United States

Recent Private Companies Transactions

Private Placement
June 2, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ardelyx, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at